MX345019B - Nuevo anticuerpo ctgf antihumano. - Google Patents

Nuevo anticuerpo ctgf antihumano.

Info

Publication number
MX345019B
MX345019B MX2014007681A MX2014007681A MX345019B MX 345019 B MX345019 B MX 345019B MX 2014007681 A MX2014007681 A MX 2014007681A MX 2014007681 A MX2014007681 A MX 2014007681A MX 345019 B MX345019 B MX 345019B
Authority
MX
Mexico
Prior art keywords
human ctgf
ctgf antibody
seq
amino acid
acid sequence
Prior art date
Application number
MX2014007681A
Other languages
English (en)
Spanish (es)
Other versions
MX2014007681A (es
Inventor
Iwasaki Shoji
Moriya Ryuichi
Yoshino Masayasu
Takakura Koji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2014007681A publication Critical patent/MX2014007681A/es
Publication of MX345019B publication Critical patent/MX345019B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2014007681A 2011-12-22 2012-12-21 Nuevo anticuerpo ctgf antihumano. MX345019B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトctgf抗体

Publications (2)

Publication Number Publication Date
MX2014007681A MX2014007681A (es) 2014-11-25
MX345019B true MX345019B (es) 2017-01-11

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007681A MX345019B (es) 2011-12-22 2012-12-21 Nuevo anticuerpo ctgf antihumano.

Country Status (16)

Country Link
US (1) US9587015B2 (enExample)
EP (1) EP2796550B1 (enExample)
JP (1) JP6040943B2 (enExample)
KR (1) KR20140107507A (enExample)
CN (1) CN104011206B (enExample)
AR (1) AR089425A1 (enExample)
BR (1) BR112014015405A2 (enExample)
CA (1) CA2859627A1 (enExample)
EA (1) EA029290B1 (enExample)
ES (1) ES2665851T3 (enExample)
IN (1) IN2014CN04615A (enExample)
MX (1) MX345019B (enExample)
PL (1) PL2796550T3 (enExample)
PT (1) PT2796550T (enExample)
TW (1) TW201333034A (enExample)
WO (1) WO2013094723A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
MY208454A (en) * 2019-06-04 2025-05-09 Shanghai hengrui pharmaceutical co ltd Anti-connective tissue growth factor antibody and application thereof
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
US20250163158A1 (en) 2022-06-07 2025-05-22 Astellas Pharma Inc. Pharmaceutical composition containing anti-integrin alpha11 antibody for treatment or prevention of aging-related diseases
WO2024095964A1 (ja) 2022-10-31 2024-05-10 アステラス製薬株式会社 Toll様受容体7/8デュアルアゴニスト化合物を含む抗体薬物複合体
TW202502816A (zh) * 2023-03-10 2025-01-16 大陸商上海濟煜醫藥科技有限公司 一種靶向ctgf的抗體或其抗原結合片段及其應用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
KR100337069B1 (ko) 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6492129B1 (en) * 1998-12-14 2002-12-10 University Of Miami Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
ES2665851T3 (es) 2018-04-27
EP2796550A4 (en) 2015-08-19
EA201491240A1 (ru) 2014-11-28
EP2796550B1 (en) 2018-02-28
PT2796550T (pt) 2018-04-18
US20140343258A1 (en) 2014-11-20
CN104011206A (zh) 2014-08-27
CA2859627A1 (en) 2013-06-27
WO2013094723A1 (ja) 2013-06-27
EP2796550A1 (en) 2014-10-29
US9587015B2 (en) 2017-03-07
CN104011206B (zh) 2017-03-08
TW201333034A (zh) 2013-08-16
KR20140107507A (ko) 2014-09-04
EA029290B1 (ru) 2018-03-30
IN2014CN04615A (enExample) 2015-09-18
JP6040943B2 (ja) 2016-12-07
AR089425A1 (es) 2014-08-20
JPWO2013094723A1 (ja) 2015-04-27
PL2796550T3 (pl) 2018-08-31
BR112014015405A2 (pt) 2017-06-13
MX2014007681A (es) 2014-11-25

Similar Documents

Publication Publication Date Title
MX345019B (es) Nuevo anticuerpo ctgf antihumano.
MX2014001370A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
NZ610734A (en) Human antibodies to the glucagon receptor
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
NZ705848A (en) Anti-cd38 antibodies
WO2009048537A3 (en) Humanized antibody
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
MX2014001627A (es) Nuevo anticuerpo anti-ngf humano.
NZ706986A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
WO2013120012A3 (en) Cdim binding proteins and uses thereof
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
NZ628943A (en) Human antibodies to clostridium difficile toxins
EP2548574A4 (en) NEW HUMANIZED MONOCLONAL ANTIBODY AGAINST CD20
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
NZ603191A (en) Methods for the treatment of il-1b related conditions
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体

Legal Events

Date Code Title Description
FG Grant or registration